The findings indicate that CRISPR-Cas9 can target multiple stages of the HIV life cycle, including disruption of viral entry coreceptors, inhibition of viral replication, and elimination of latent proviral DNA integrated within host genomes.
Background: Human Immunodeficiency Virus (HIV) remains a major global health challenge with high morbidity and mortality rates. Although antiretroviral therapy (ART) effectively suppresses viral replication, it is unable to eradicate latent HIV reservoirs, preventing complete viral clearance. Advances in genome editing...
M. R. Hidayatullah, Salwa Adilah Ningtiyas, Adinda Nezma Meidina et al.· SCRIPTA SCORE Scientific Med...· 0 citations
Background: Human Immunodeficiency Virus (HIV) remains a major global public health challenge. According to the World Health Organization (WHO), in 2025, approximately 41 million people were living with HIV, with an estimated 570,000 deaths attributable to HIV-related causes and 1.2 million new HIV infections. These fi...
M. R. Hidayatullah, Adinda Nezma Meidina, Salwa Adilah Ningtiyas et al.· SCRIPTA SCORE Scientific Med...· 0 citations
Emerging findings indicated that Cas13-based constructs can efficiently reduce HIV RNA levels and blunt viral gene expression, though durable impacts on reservoir size and clinical remission remain to be demonstrated.
Mukisa Ian Mugaiga· IDOSR Journal of Applied Sci...· 0 citations
The mechanisms of CRISPR/Cas action and its applications in hematologic malignancies, breast cancer, colorectal cancer, gastric cancer, and lung cancer are explored.
M. Omarov, E. Karacheva, M. M. Arapieva et al.· Сибирский научный медицински...· 0 citations
HIV-SCRIBE is developed, a CRISPR-based molecular recorder in which a self-targeting guide RNA locus is placed under a Tat-responsive minimal HIV-1 5'LTR promoter, coupling Cas9-mediated cleavage and error-prone repair to Tat-driven transcriptional activation to generate a durable molecular record of HIV-1 reactivation...
Nahia Urturi Ortiz, M. Nonnemacher, Brian Wigdahl· 0 citations
A major focus of this review is the inclusion of recent hybrid systems (VLPs, SORT-LNPs) and the recognition that chemical modification of guide RNAs is a critical parameter for therapeutic success and that hybrid systems and stimuli-responsive nanoparticles are poised to dominate the next 5 years of clinical developme...
M. Rezaee, F. Izadi, Saeed Nobaharian et al.· Beni-Suef University Journal...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
